ASH 2022 | The prognostic impact of TP53 and IgHV status in the era of targeted therapies in CLL
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, St. Vincent’s Hospital, University of Melbourne, Melbourne, Australia, discusses the importance of continuing genomic testing in chronic lymphocytic leukemia (CLL) with the advent of targeted therapies. Indeed, evidence has shown that IgHV and TP53 mutation status does still have a prognostic value in patients treated with venetoclax and obinutuzumab, and venetoclax and ibrutinib. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
Explore our dedicated feature on genomic testing in CLL here: http://bit.ly/403y417
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Beigene: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; LOXO: Honoraria; AstraZeneca: Honoraria; Janssen: Honoraria, Research Funding.
